RP Cure Tracker

Trials / NCT07265895

Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations

Not yet recruiting Observational Natural history / observational

Sponsor
IRCCS San Raffaele
Treatment
No Intervention: Observational Cohort
Gene
BEST1, PRPH2, RPE65, RPGR, USH2A
Conditions
Retinal Degenerations, Retinitis Pigmentosa (RP), Stargardt Disease
Ages
Any to no upper limit
Enrollment
200 participants
Started
2026-01-01
Main results expected
2028-12-31
Results posted
Not yet
Record last updated
2025-12-05

What the study is testing

Inherited Retinal Diseases (IRDs) are a heterogeneous group of genetically based degenerative retinal disorders, representing a major cause of visual impairment and blindness in working-age adults. Despite the approval of the first gene therapy for RPE65-related IRD (voretigene neparvovec) in 2017, most IRDs remain untreatable, though many gene therapies are in development. Effective trial design and therapy development require a deep understanding of disease natural history and genotype-phenotype correlations. Over 270 IRD-associated genes are known (e.g., ABCA4, USH2A, RPGR, PRPH2, BEST1), each linked to distinct phenotypes and clinical progression. This retrospective study analyzes clinical, functional, and imaging data (Optical Coherence Tomography, Fundus Autofluorescence, Microperimetry) from a large, genetically characterized IRD cohort at the IRCCS Ospedale San Raffaele up to December 31, 2025. The aims are to describe natural history, define genotype-phenotype relationships, and identify structural and functional outcome measures useful for future clinical trial endpoints, supporting personalized prognosis and trial design.

Where it runs

Italy (1)

Open on ClinicalTrials.gov for contacts and eligibility